Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development

Area of Science:

• Oncology
• Cancer Research
• Drug Development

Background:

• Antibody drug conjugates (ADCs) are effective in various cancers.
• The potential of ADCs in cholangiocarcinoma (CCA) remains unexplored.
• Identifying suitable molecular targets is crucial for ADC therapy in CCA.

Purpose of the Study:

• To investigate the expression of potential ADC targets in cholangiocarcinoma (CCA) tumors.
• To evaluate the suitability of TROP2, NECTIN4, B7-H3, and CLDN18.2 as targets for ADC therapy in CCA.
• To assess the impact of IDH1 mutations on ADC target expression in CCA.

Main Methods:

• Profiling of 23 cholangiocarcinoma (CCA) tumor samples.
• Immunohistochemical analysis to determine the expression levels and localization of TROP2, NECTIN4, B7-H3, and CLDN18.2.
• Correlation analysis between target expression and IDH1 mutation status.

Main Results:

• High expression of TROP2 (82.6%) was observed, but also in benign epithelium.
• NECTIN4 showed tumor-specific staining in 65.2% of cases, indicating high selectivity.
• B7-H3 (47.8%) and CLDN18.2 (13.0%) were less frequently expressed. IDH1-mutant tumors had lower expression of these ADC targets.

Conclusions:

• NECTIN4 is a promising tumor-specific target for antibody drug conjugate (ADC) therapy in cholangiocarcinoma (CCA).
• While TROP2 is highly expressed, its presence in benign tissues may limit selectivity.
• ADC strategies warrant further investigation in CCA, particularly targeting NECTIN4, considering the impact of IDH1 mutations on target expression.